Aoxing Pharmaceutical Company, Inc. / Fundamentals
Income statement
- Net revenue
€25.68M - Cost of goods sold
€6.11M - Gross profit
€19.56M - SG&A expenses
€16.19M - R&D expenses
€2.13M - EBITDA
€1.68M - D&A
€841.39K - EBIT
€825.31K - Interest expenses
€546.23K - EBT
-€1.59M - Tax expenses
-€348.96K - Net income
-€1.25M
Cash flow statement
- Net deferred tax
-€743.51K - Non-cash items
€58.60K - Changes in working capital
-€3.84M - Operating cash flow
-€1.16M - Capex
€25.82K - Other investing cash flow
€0.00 - Net investing cash flow
-€25.82K - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€2.44M - Other financing cash flow
€0.00 - Net financing cash flow
€2.44M - Foreign exchange effects
-€370.36K - Net change in cash
€882.07K - Cash at end of period
€6.04M - Free cash flow
-€1.14M
Balance sheet
- Cash and cash equivalents
€6.04M - Cash and short-term investments
€6.04M - Total receivables
€13.04M - Inventory
€2.05M - Other current assets
€8.55M - Total current assets
€29.69M - Property, plant & equipment
€20.50M - Goodwill
€0.00 - Intangible assets
€1.53M - Long-term investments
-€1.56K - Other non-current assets
€1.56K - Total non-current assets
€23.60M - Total assets
€53.28M - Accounts payable
€3.62M - Short-term debt
€23.56M - Other current liabilities
€7.16M - Total current liabilities
€37.51M - Long-term debt
€85.40K - Deferred tax liabilities
-€263.90 - Other non-current liabilities
€0.00 - Total non-current liabilities
€349.30K - Total liabilities
€37.85M - Common stock
€65.00K - Retained earnings
-€47.64M - Other equity
€1.06M - Total equity
€15.43M - Total liabilities and shareholders' equity
€53.28M
Company information
- Market capitalization
€487.52K - Employees
346
Company ratios
- Gross margin
-
76.2% Much better than peer group: 28.2% - EBITDA margin
-
6.5% Better than peer group: -5.2% - EBIT margin
-
3.2% Better than peer group: -10.9% - EBT margin
-
-6.2% Even with peer group: -10.6% - Net margin
-
-4.9% Better than peer group: -11.6% - ROE
-
-8.1% Better than peer group: -18.6% - ROA
-
-2.3% Even with peer group: -1.7% - Asset turnover
-
48.2% Much worse than peer group: 83.7% - FCF margin
-
-4.6% Much better than peer group: -30.2% - FCF yield
-243.9% - Efficiency ratio
93.5% - Net sales per employee
-
€74.21K - Net income per employee
-
-€3.61K